doxycycline - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.39 [0.11, 1.42]< 10%2 studies (2/-)92.3 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.44 [0.24, 0.78]< 10%2 studies (2/-)99.7 %some concernnot evaluable moderateimportant-
clinical improvement 1.89 [1.06, 3.38]> 10%1 study (1/-)98.4 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.93 [1.27, 2.93]> 10%1 study (1/-)99.9 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.89 [1.06, 3.38]> 10%1 study (1/-)98.4 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 3.97 [0.18, 88.58]< 10%1 study (1/-)19.5 %some concernnot evaluable moderateimportant-
adverse events 18.57 [1.07, 322.77]< 10%1 study (1/-)2.4 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.